[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100442909":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":50,"collaborators":20,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":20,"eligibilityCriteria":60,"healthyVolunteers":61,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":20,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":20,"overallStatus":30,"whyStopped":20,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Chinese Academy of Sciences","OTHER_GOV",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Anti-GPC3-IRDye800CW Intraoperative Fluorescence","EXPERIMENTAL","The patients will receive an injection of fluorophore (Anti-GPC3-IRDye800CW) before the surgery. Then intraoperative fluorescence imaging will be performed to guide lesion resection.",[13],"Drug: Anti-GPC3-IRDye800CW",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Anti-GPC3-IRDye800CW","Drug Injection: Anti-GPC3-IRDye800CW",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Zeyu Zhang, Ph.D.","CONTACT","86-18201082715","zhangzeyu@fingerpass.net.cn",[28,41],{"facility":29,"status":30,"city":31,"state":32,"zip":20,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":20},"Zhuhai People's Hospital","RECRUITING","Zhuhai","Guangdong","China","CN",{"type":36,"coordinates":37},"Point",[38,39],113.56778,22.27694,{"lat":39,"lon":38},{"facility":42,"status":30,"city":43,"state":44,"zip":20,"country":33,"countryCode":34,"cosmosGeoPoint":45,"geoPoint":49,"contacts":20},"The Affiliated Hospital of Southwest Medical University","Luzhou","Sichuan",{"type":36,"coordinates":46},[47,48],105.42575,28.8903,{"lat":48,"lon":47},{"type":51,"investigatorFullName":52,"investigatorTitle":53,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"PRINCIPAL_INVESTIGATOR","Zeyu Zhang, PHD","Principal Investigator","100442909","gpc3-targeted-fluorescence-image-guided-surgery-of-hepatocellular-carcinoma-100442909",false,"NCT05047510","GPC3 Targeted Fluorescence Image Guided Surgery of Hepatocellular Carcinoma","An Evaluation Study of GPC3 Targeted Fluorescence Imaging to Guide the Surgery of Hepatocellular Carcinoma","Inclusion Criteria:\n\n1. Patients who have been diagnosed with hepatocellular carcinoma.\n2. Planned to receive hepatectomy.\n3. Liver function Child-Pugh A\u002FB.\n4. GPC-3 was validated highly expressed preoperatively.\n5. Aged 18 to 75, and the expected lifetime is longer than 6 months.\n6. Approved to sign the informed consent.\n\nExclusion Criteria:\n\n1. Allergic to IRDye800.\n2. Enrolled in other trials in the past 3 months.\n3. Another malignant tumor was found.\n4. Undesirable function of heart, lung, kidney, or any other organs.\n5. Unable to tolerate a hepatectomy.\n6. The researchers considered inappropriate to be included.",true,"ALL","18 Years","75 Years",{"count":66,"type":67},60,"ESTIMATED","INTERVENTIONAL",[70],"NA","This study is to evaluate whether intraoperative fluorescence imaging targeting GPC3 can aid improve the surgical accuracy of hepatocellular carcinoma.\n\nThe main purposes of this study include:\n\n① To raise the detection rate of hepatocellular carcinoma intraoperatively using the novel NIR-II fluorescence molecular imaging and the GPC-3 targeted fluorophore.\n\n② To validate the safety and effectiveness of the designed GPC-3 targeted fluorophore for clinical application.",[73],"Hepatocellular Carcinoma","2023-08-28",{"date":76,"type":77},"2023-08-30","ACTUAL",{"date":79,"type":77},"2021-09-10",{"date":81,"type":67},"2026-12-31",{"name":5,"class":6},2]